Cartherics is pleased to announce that Professor Alan Trounson AO, Deputy Chair, will deliver an invited lecture at King Abdullah University of Science and Technology (KAUST) titled: A Platform Technology for Immune Targeting Cancer and Endometriosis – A Women’s Health Focus. The lecture will take place on February 4, at 10.30am (AST).

In this lecture, Professor Trounson will outline how advances in allogeneic immune cell therapies are opening new frontiers in the treatment of solid tumours and chronic diseases that disproportionately affect women, including ovarian cancer and endometriosis.

While CAR-T cell therapies have transformed outcomes in haematological cancers, their impact in solid tumours has been constrained by toxicity, manufacturing complexity and limited efficacy. Professor Trounson will describe how natural killer (NK) cell–based therapies, particularly those derived from induced pluripotent stem cells (iPSCs), offer a scalable, off-the-shelf alternative with the potential to overcome many of these limitations.

The lecture will focus on Cartherics’ proprietary gene-edited iPSC-derived CAR-NK platform, including lead programs targeting tumour-associated glycoprotein-72 (TAG-72) and Tissue Factor (TF). Preclinical data demonstrating strong cytotoxic activity of Cartherics’ lead candidate CTH-401 in ovarian cancer models, as well as programs in endometriosis and other solid tumours, will be discussed. Emerging work on AI-designed, multi-gene-edited CAR-NK therapies aimed at improving tumour homing and overcoming immunosuppression in the solid tumour microenvironment will also be presented.

The lecture will highlight Cartherics’ commitment to advancing innovative immune cell therapies for cancers and chronic diseases with significant unmet need, particularly in women’s health.

Prof. Alan Trounson AO commented: “This NK cell platform has the prospects of delivering new cell-based therapeutics for cancer and endometriosis rapidly and effectively.”